Literature DB >> 28391613

Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.

Naoko Wada1, Hiroshi Uchi1, Masutaka Furue1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28391613     DOI： 10.1111/1346-8138.13840

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  10 in total

1.  A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Authors:  Jason M Redman; Logan P Rhea; Lisa Cordes; Helen Owens; Ravi A Madan; Marijo Bilusic; James L Gulley; Jung-Min Lee; William L Dahut; Fatima Karzai
Journal:  Clin Genitourin Cancer       Date:  2019-02-14       Impact factor: 2.872

Review 2.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

3.  RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.

Authors:  Sang T Kim; William A Murphy; Ana Aparicio; Sumit K Subudhi
Journal:  J Immunother Precis Oncol       Date:  2020-05-14

4.  Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Authors:  Jonathan E Lu; Jessica R Chang; Jesse L Berry; Gino K In; Sandy Zhang-Nunes
Journal:  Int Ophthalmol Clin       Date:  2020

Review 5.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

6.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

7.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

8.  Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma.

Authors:  Akihiro Yoshimura; Kazuaki Yamanaka; Rei Tadokoro; Teppei Wakita; Shota Fukae; Takahiro Yoshida; Masahiro Sekiguchi; Hidefumi Kishikawa
Journal:  IJU Case Rep       Date:  2022-05-03

9.  Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.

Authors:  Alison Taylor; Christopher E Rudd
Journal:  J Immunol Sci       Date:  2019-05-07

10.  Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy.

Authors:  Shintaro Yamamoto; Shunichi Fujita; Tomoyuki Mukai; Hiroshi Sawachika; Yoshitaka Morita
Journal:  Intern Med       Date:  2019-10-31       Impact factor: 1.271
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.